N@N

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

The article from Insider Monkey discusses why Recursion Pharmaceuticals (RXRX) is considered the worst ARK stock to buy according to short sellers. Recursion, a company focused on using AI to accelerate drug discovery, has seen its stock plummet by 60% in the last year. Despite its innovative approach, the company has not yet turned a profit, with a reported net loss of $117.1 million in the first nine months of 2023. Short interest in RXRX has surged, with 25.7% of its float being shorted, indicating significant skepticism from investors about its future profitability and business model. The article highlights concerns over the company's high cash burn rate, the speculative nature of its AI-driven drug discovery process, and the lack of near-term revenue prospects, all of which contribute to its status as a risky investment in the eyes of short sellers.

Read the Full Insider Monkey Article at:
[ https://www.insidermonkey.com/blog/why-recursion-pharmaceuticals-rxrx-is-the-worst-ark-stock-to-buy-according-to-short-sellers-1405737/ ]